Nathan Bryson, PhD

Nathan Bryson, PhD, is the Chief Scientific Officer at Reunion Neuroscience, a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions for underserved mental health conditions.3

As Chief Scientific Officer, Dr. Bryson plays a key role in Reunion's drug development efforts, particularly in advancing the company's lead asset, RE104. This proprietary compound is a novel serotonergic psychedelic being developed as a potential treatment for postpartum depression.12

Dr. Bryson's expertise lies in neuroscience drug development. He has been instrumental in the preclinical studies of RE104, co-authoring a paper titled "RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4‑Hydroxy‑N,N‑diisopropyltryptamine" published in ACS Chemical Neuroscience.2

His work at Reunion Neuroscience involves pushing the boundaries of neuroscience to develop innovative therapeutic solutions. The company is currently evaluating RE104 in a Phase 2 clinical trial (RECONNECT) for postpartum depression and is also investigating its potential in other neuropsychiatric indications.2

Dr. Bryson's LinkedIn profile confirms his role as Chief Scientific Officer at Reunion Neuroscience, and his username on the platform is indeed nathanbryson.4 He is based in Toronto and has over 500 connections on LinkedIn.4

In addition to his scientific contributions, Dr. Bryson is also involved in protecting Reunion's intellectual property. He was named as the original and sole inventor of Reunion's RE104 compound in a lawsuit filed by the company against Mindset Pharma Inc. regarding patent ownership.1